Search Results

The Monobind AccuBind Neo-TSH Microwell Elisa Assay is an in vitro diagnostic test system for the quantitative determination of thyroid stimulating hormone (TSH) in human whole blood dried on Whatman 903 filter paper. It is intended to be used to screen newborns for congenital hypothyroidism.

The Monobind AccuBind™ Neonatal TSH Elisa Assay is a solid phase two-site immunoenzymometric assay based on the direct sandwich technique in which two specific antibodies are directed against two separate antigenic determinants on the hTSH molecule. In this method, TSH dried whole blood callbrator, patient specimen or control is first added to a streptavidin coated well. Elution buffer containing biotinylated monoclonal antibodies are added and the reactants mixed. Reaction between the biotinylated Anti-TSH and the TSH in the dried blood spot forms a complex that binds to the streptavidin coated to the inherent affinity of streptavidin and biotin. After the completion of the first incubation period, excess reactants are washed off via a wash step and the enzyme conjugate (another specific anti-TSH antibody linked to an enzyme) is added to the Ag-Ab complex deposited on the plastic surface. The enzyme labeled Anti-TSH antibody binds to the TSH making a sandwich complex with two antibodies bound to the antigen during a second incubation. The microplate is washed to remove unreacted enzyme. Finally, the activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce color.

The provided document describes the Monobind AccuBind Neo-TSH Microwell Elisa Kit, an in vitro diagnostic test system for screening newborns for congenital hypothyroidism by quantitatively determining thyroid stimulating hormone (TSH) in dried whole blood.

Here's an analysis of the acceptance criteria and the study that proves the device meets them:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state pre-defined "acceptance criteria" in terms of specific thresholds for agreement or performance metrics. Instead, it relies on a comparative effectiveness study against a predicate device to demonstrate substantial equivalence. The implicit acceptance criterion is that the new device's performance should be comparable to the predicate device.

2. Sample Size and Data Provenance for the Test Set

• Sample Size: 158 newborn samples.
• Data Provenance: The document does not explicitly state the country of origin. It is a retrospective comparison as the samples were measured with both the new device and the existing predicate device.

3. Number of Experts and Qualifications for Ground Truth

• The document does not mention the use of experts to establish ground truth. The comparison is made against a legally marketed predicate device, with its results serving as the reference for comparison.

4. Adjudication Method for the Test Set

• None specified. The study compares the measurements of two different assay methods directly. There is no indication of an adjudication process to reconcile discrepancies between the two device readings.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

• No, an MRMC study was not done. This is an in vitro diagnostic test for measuring TSH levels. The study involves comparing the quantitative results of two different assay kits on a set of samples, not the interpretation of results by human readers. Therefore, the concept of "human readers improving with AI vs without AI assistance" is not applicable here.

6. Standalone (Algorithm Only) Performance

• Yes, a standalone performance was done. The Monobind AccuBind Neo-TSH Microwell Elisa Kit is an in vitro diagnostic test, and its performance (quantitative measurement of TSH) is assessed as a standalone device by comparing its output with that of a predicate device. The results (hTSH concentrations) are directly generated by the assay kit.

7. Type of Ground Truth Used

• The ground truth used is effectively the results obtained from the legally marketed predicate device (Neonatal TSH RIA Kit (I-125) 510(k)# K772192). The study's objective is to show substantial equivalence to this predicate device. This is a form of "reference standard" or "comparator device" ground truth.

8. Sample Size for the Training Set

• The document does not provide information regarding a "training set" or its sample size. This type of device (Elisa kit) typically undergoes analytical validation and clinical validation. While some internal development (which could involve "training" in a broad sense for assay optimization) would have occurred, the document focuses on the premarket notification and equivalence comparison, which uses a test set of 158 samples. It's unlikely that a distinct "training set" as understood in machine learning contexts would be explicitly reported for this type of IVD.

9. How Ground Truth for the Training Set Was Established

• As no training set is discussed or explicitly defined in the document, no information is provided on how its ground truth would have been established.

Ask a specific question about this device